Axa S.A. Reata Pharmaceuticals Inc Transaction History

Axa S.A.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$30.85 - $93.17 $83,295 - $251,559	2,700 New	2,700 $245,000
Q4 2022 Feb 14, 2023	SELL	$22.15 - $42.11 $279,090 - $530,586	-12,600 Closed	0 $0
Q3 2022 Nov 14, 2022	BUY	$19.41 - $36.49 $244,566 - $459,774	12,600 New	12,600 $317,000
Q3 2020 Nov 13, 2020	SELL	$93.53 - $163.34 $271,237 - $473,686	-2,900 Closed	0 $0
Q2 2020 Aug 14, 2020	SELL	$126.3 - $176.56 $303,120 - $423,744	-2,400 Reduced 45.28%	2,900 $452,000
Q1 2020 May 15, 2020	BUY	$124.16 - $247.74 $658,048 - $1.31 Million	5,300 New	5,300 $765,000
Q2 2019 Aug 13, 2019	SELL	$77.72 - $94.35 $373,056 - $452,880	-4,800 Closed	0 $0
Q1 2019 May 14, 2019	BUY	$51.9 - $101.79 $249,120 - $488,592	4,800 New	4,800 $410,000

62.7K

Ticker RETA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,583,200
Description
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney diseas...

Get notified when there are updates to the investment portfolio of Axa S.A., based on Form 13F filings with the SEC.

Stay updated on Axa S.A. with notifications on news.